Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic chemotherapy.

V M Klimek1, J D Wolchok, P B Chapman

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Clinics in Plastic Surgery
|August 15, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Science (New York, N.Y.)·2017
Same author

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same journal

Lower-Extremity Reconstruction: Principles, Progress, and Perspectives.

Clinics in plastic surgery·2026
Same journal

Pediatric.

Clinics in plastic surgery·2026
Same journal

Lower Extremity Reconstruction in Acute Burns.

Clinics in plastic surgery·2026
Same journal

Chronic Lower Extremity Wounds: Updates on Lower Extremity Reconstruction in Clinics in Plastic Surgery.

Clinics in plastic surgery·2026
Same journal

Updates in Lower Extremity Reconstruction: Post Sarcoma.

Clinics in plastic surgery·2026
Same journal

Fillet Flaps for Lower Extremity Salvage.

Clinics in plastic surgery·2026
See all related articles

Systemic chemotherapy for metastatic melanoma offers palliative care. Current treatments like dacarbazine (DTIC) and combination therapies show limited durable remission or survival benefits, necessitating improved strategies.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Metastatic melanoma treatment primarily relies on palliative systemic chemotherapy.
  • Dacarbazine (dimethyl-1-triazeno imidazole-4-carboxamide [DTIC]) is the established standard chemotherapy for advanced melanoma.
  • Existing combination chemotherapy and biochemotherapy regimens have not yielded significant improvements in durable remission or overall survival.

Purpose of the Study:

  • To review the current landscape of systemic chemotherapy for metastatic melanoma.
  • To highlight the limitations of existing treatment strategies.
  • To underscore the need for more effective and less toxic therapeutic options.

Main Methods:

  • Literature review of systemic chemotherapy in metastatic melanoma.

Related Experiment Videos

  • Analysis of response rates, remission durability, and survival data for standard and combination regimens.
  • Evaluation of treatment toxicity profiles.

    • Main Results:

    • Dacarbazine (DTIC) remains the primary palliative chemotherapy agent for advanced melanoma.
    • Combination regimens demonstrate higher initial response rates but fail to achieve durable remissions or improve survival.
    • Current systemic therapies lack the desired efficacy and possess significant toxicity.

    Conclusions:

    • The current systemic chemotherapy approaches for metastatic melanoma are inadequate.
    • There is a critical unmet need for novel, more effective, and less toxic treatment strategies.
    • Further research into advanced melanoma systemic therapy is essential.